Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-305-7777
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.52 million
Profitability
Miscellaneous
Employees272
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics Inc (NASDAQ:FLXN) issued its quarterly earnings data on Tuesday, August, 6th. The specialty pharmaceutical company reported ($0.96) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.06) by $0.10. The specialty pharmaceutical company earned $16.95 million during the quarter, compared to analyst estimates of $14.03 million. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. View Flexion Therapeutics' Earnings History.
When is Flexion Therapeutics' next earnings date?
What price target have analysts set for FLXN?
7 equities research analysts have issued 12 month price targets for Flexion Therapeutics' shares. Their predictions range from $18.00 to $36.00. On average, they anticipate Flexion Therapeutics' stock price to reach $25.50 in the next year. This suggests a possible upside of 79.1% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.
What is the consensus analysts' recommendation for Flexion Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.
What are Wall Street analysts saying about Flexion Therapeutics stock?
Here are some recent quotes from research analysts about Flexion Therapeutics stock:
- 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (10/8/2019)
- 2. Northland Securities analysts commented, "We believe Zilretta’s superior safety and efficacy vs. IR-corticosteroids will make it the intra-articular injection of choice for treating OAK and other indications. We anticipate approval of the sNDA for repeat administration for OAK in mid-October. This, along w/ Zilretta receipt of J code (J3304) effective Co.’s pursuit of additional indications, i.e., hip and shoulder, we believe will support peak US sales >$750MM. Flexion reported 4Q Zilretta sales of $9.5MM, aligned w/ consensus. R&D and SG&A expense line items for the 4Q period totaled $14.9MM and $30.6MM, respectively, w/ EPS for the 4Q period at ($1.07) vs. the ($1.15) consensus." (3/1/2019)
Has Flexion Therapeutics been receiving favorable news coverage?
Media headlines about FLXN stock have trended somewhat positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Flexion Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Flexion Therapeutics.
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Xencor (XNCR), Ligand Pharmaceuticals (LGND), Cambrex (CBM), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Prestige Consumer Healthcare (PBH), Apellis Pharmaceuticals (APLS), Akcea Therapeutics (AKCA) and Tricida (TCDA).
What other stocks do shareholders of Flexion Therapeutics own?
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the folowing people:
- Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)
- Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)
- Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)
- Mr. David A. Arkowitz, Chief Financial Officer (Age 58)
- Scott Young, VP of Corp. Communications & Investor Relations
Who are Flexion Therapeutics' major shareholders?
Flexion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (2.05%), Selz Capital LLC (0.89%) and Campbell Capital Management Inc. (0.34%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.
Which major investors are selling Flexion Therapeutics stock?
FLXN stock was sold by a variety of institutional investors in the last quarter, including Selz Capital LLC. Company insiders that have sold Flexion Therapeutics company stock in the last year include David Arkowitz, Mark S Levine and Michael D Clayman. View Insider Buying and Selling for Flexion Therapeutics.
Which major investors are buying Flexion Therapeutics stock?
FLXN stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Campbell Capital Management Inc.. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Michael D Clayman, Neil Bodick and Samuel D Colella. View Insider Buying and Selling for Flexion Therapeutics.
How do I buy shares of Flexion Therapeutics?
Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Flexion Therapeutics' stock price today?
One share of FLXN stock can currently be purchased for approximately $14.24.
How big of a company is Flexion Therapeutics?
Flexion Therapeutics has a market capitalization of $542.69 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe.View Additional Information About Flexion Therapeutics.
What is Flexion Therapeutics' official website?
How can I contact Flexion Therapeutics?
Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]
MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
